Cover Image
市場調查報告書

Tillotts Pharma AG的產品平台分析

Tillotts Pharma AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293952
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Tillotts Pharma AG的產品平台分析 Tillotts Pharma AG - Product Pipeline Review - 2015
出版日期: 2015年02月28日 內容資訊: 英文 25 Pages
簡介

Tillotts Pharma AG是總公司設置於瑞士的製藥企業,從事消化器官系統疾病領域的創新製藥產品,醫療設備,診斷藥等之開發,轉出授權,銷售務。開發對象疾病有潰瘍性結腸炎,克隆氏症,腸痙攣等五花八門。

本報告提供Tillotts Pharma AG 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Tillotts Pharma AG 基本資料

  • Tillotts Pharma AG 概要
  • 主要資訊
  • 企業資料

Tillotts Pharma AG :R&D概要

  • 主要的治療範圍

Tillotts Pharma AG :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Tillotts Pharma AG :開發中產品概況

  • 後期階段的開發中產品
    • 登記前階段的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Tillotts Pharma AG:藥物簡介

  • mesalamine CR
  • mesalamine
  • TP-08
  • TP-10

Tillotts Pharma AG :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Tillotts Pharma AG :最新的開發平台資訊

Tillotts Pharma AG :開發暫停中的計劃

Tillotts Pharma AG :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06806CDB

Summary

Global Markets Direct's, 'Tillotts Pharma AG - Product Pipeline Review - 2015', provides an overview of the Tillotts Pharma AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tillotts Pharma AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Tillotts Pharma AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Tillotts Pharma AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Tillotts Pharma AG's pipeline products

Reasons to buy

  • Evaluate Tillotts Pharma AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Tillotts Pharma AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Tillotts Pharma AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Tillotts Pharma AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tillotts Pharma AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Tillotts Pharma AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Tillotts Pharma AG Snapshot
    • Tillotts Pharma AG Overview
    • Key Information
    • Key Facts
  • Tillotts Pharma AG - Research and Development Overview
    • Key Therapeutic Areas
  • Tillotts Pharma AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Tillotts Pharma AG - Pipeline Products Glance
    • Tillotts Pharma AG - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Tillotts Pharma AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Tillotts Pharma AG - Drug Profiles
    • mesalamine CR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mesalamine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-08
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-10
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tillotts Pharma AG - Pipeline Analysis
    • Tillotts Pharma AG - Pipeline Products by Target
    • Tillotts Pharma AG - Pipeline Products by Route of Administration
    • Tillotts Pharma AG - Pipeline Products by Molecule Type
    • Tillotts Pharma AG - Pipeline Products by Mechanism of Action
  • Tillotts Pharma AG - Recent Pipeline Updates
  • Tillotts Pharma AG - Dormant Projects
  • Tillotts Pharma AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Tillotts Pharma AG, Key Information
  • Tillotts Pharma AG, Key Facts
  • Tillotts Pharma AG - Pipeline by Indication, 2015
  • Tillotts Pharma AG - Pipeline by Stage of Development, 2015
  • Tillotts Pharma AG - Monotherapy Products in Pipeline, 2015
  • Tillotts Pharma AG - Pre-Registration, 2015
  • Tillotts Pharma AG - Phase III, 2015
  • Tillotts Pharma AG - Preclinical, 2015
  • Tillotts Pharma AG - Pipeline by Target, 2015
  • Tillotts Pharma AG - Pipeline by Route of Administration, 2015
  • Tillotts Pharma AG - Pipeline by Molecule Type, 2015
  • Tillotts Pharma AG - Pipeline Products by Mechanism of Action, 2015
  • Tillotts Pharma AG - Recent Pipeline Updates, 2015
  • Tillotts Pharma AG - Dormant Developmental Projects,2015
  • Tillotts Pharma AG, Other Locations
  • Tillotts Pharma AG, Subsidiaries

List of Figures

  • Tillotts Pharma AG - Pipeline by Top 10 Indication, 2015
  • Tillotts Pharma AG - Pipeline by Stage of Development, 2015
  • Tillotts Pharma AG - Monotherapy Products in Pipeline, 2015
  • Tillotts Pharma AG - Pipeline by Top 10 Target, 2015
  • Tillotts Pharma AG - Pipeline by Top 10 Route of Administration, 2015
  • Tillotts Pharma AG - Pipeline by Top 10 Molecule Type, 2015
  • Tillotts Pharma AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top